Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies

Welcome and Introduction

The Front Lines: Effectively Utilizing Biomarkers to Predict Optimal NSCLC Management Immunotherapy

Recent Evidence of Immunotherapies in Resectable NSCLC

Determining the Role of Immunotherapy in Patients Unresectable NSCLC

Where Immune Checkpoint Inhibition Fits in the Treatment Paradigm of Metastatic NSCLC